Insulin Human
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Insulin Human: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin human is a replacement hormone originally used to treat type 1 and type 2 diabetes mellitus and diabetic ketoacidosis. The TxGNN model predicts it may be effective for autoimmune oophoritis, but no clinical trials and no publications currently support this prediction. The prediction rests on knowledge-graph signals alone and is best read as a hypothesis rather than a therapeutic lead.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis (the registered indication text for the Singapore product is not available) |
| Predicted New Indication | Autoimmune oophoritis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, insulin human is a recombinant human insulin whose efficacy in diabetes mellitus is well established, and it acts through insulin receptor signaling to regulate glucose and lipid metabolism.
A plausible but unproven link is that insulin signaling influences ovarian granulosa cell function and steroidogenesis. A more likely explanation is comorbidity. Autoimmune oophoritis is immune-mediated and often occurs within autoimmune polyendocrine syndromes that include type 1 diabetes. The model may therefore be picking up a disease-association pattern rather than a therapeutic effect of insulin.
Other top-ranked predictions show similar patterns:
- Stiff person syndrome and focal stiff limb syndrome (scores 99.81%): linked to anti-GAD65 autoimmunity and type 1 diabetes comorbidity. Insulin would treat the diabetes, not the neurological disease.
- Thiamine-responsive dysfunction syndrome and pancreatic agenesis: insulin already manages the associated diabetes, so these are extensions of the existing indication rather than new uses.
- Localized lipodystrophies (drug-induced, centrifugal, pressure-induced, idiopathic): injection-site lipodystrophy is a known adverse effect of subcutaneous insulin, so these predictions may reflect adverse-effect associations.
- Opsismodysplasia: a theoretical link exists through INPPL1 (SHIP2), a regulator of insulin/PI3K signaling, but there is no evidence that exogenous insulin helps.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02395P | ACTRAPID INJECTION 100 IU/ml | Injection | Not stated in the available data |
Safety Considerations
- Drug Interactions: 100 interactions were recorded. The ones listed below are examples, not the full list, and most are Moderate:
- Sympathomimetics and bronchodilators: phenylephrine, pseudoephedrine, epinephrine, salbutamol
- Other antidiabetic agents: metformin, pioglitazone, alogliptin, albiglutide
- Corticosteroids and hormones: hydrocortisone, estradiol, ethinylestradiol
- Cardiovascular and other drugs: acebutolol, benazepril, hydrochlorothiazide, acetazolamide, doxycycline, alpelisib
- Ethanol (Moderate)
- Minor: topical hydrocortisone and topical alclometasone
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a knowledge-graph score, with no clinical trials or literature. The likely drivers are autoimmune comorbidity with type 1 diabetes and disease-similarity propagation, not a therapeutic mechanism of insulin.
To proceed, the following is needed:
- Retrieval of the package insert (warnings, contraindications, approved indication) from the HSA website
- Detailed mechanism of action data for insulin human
- A literature and trial search specific to autoimmune oophoritis, including whether any insulin-related benefit has been reported beyond glycaemic control
- Review of the drug's relevance and route compatibility for the predicted condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.